Poseida Therapeutics, Inc. Proceeds from Short-term Debt
Poseida Therapeutics, Inc. reported Proceeds from Short-term Debt of $30.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromShortTermDebt · last filed 2024-03-07
- Poseida Therapeutics, Inc. proceeds from short-term debt for the quarter ending 2022-12-31 was $0.00.
- Poseida Therapeutics, Inc. proceeds from short-term debt for the quarter ending 2022-09-30 was $0.00.
- Poseida Therapeutics, Inc. proceeds from short-term debt for the quarter ending 2022-06-30 was $0.00.
- Poseida Therapeutics, Inc. proceeds from short-term debt for the quarter ending 2022-03-31 was $30.00M.
- Poseida Therapeutics, Inc. proceeds from short-term debt for fiscal 2022 was $30.00M.
- Poseida Therapeutics, Inc. proceeds from short-term debt for fiscal 2019 was $10.00M.
| Period end | Proceeds from Short-term Debt 3 month | Proceeds from Short-term Debt 6 month | Proceeds from Short-term Debt 9 month | Proceeds from Short-term Debt 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $0.00 derived: sum of 2 quarters · filed 2024-03-07 | $0.00 derived: sum of 3 quarters · filed 2024-03-07 | $30.00M 10-K · filed 2024-03-07 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $30.00M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $30.00M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $30.00M 10-Q · filed 2023-05-09 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $0.00 derived: sum of 2 quarters · filed 2021-03-11 | $10.00M 10-K · filed 2021-03-11 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $10.00M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $10.00M 10-Q · filed 2020-08-20 |